
Feb 19 (Reuters) - Alto Neuroscience Inc ANRO.N:
ALTO NEUROSCIENCE ANNOUNCES U.S. PATENT GRANTED COVERING ALTO-300 AS A TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER CHARACTERIZED BY AN ELECTROENCEPHALOGRAM BIOMARKER
Source text: ID:nBw56gCPna
Further company coverage: ANRO.N